<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461422</url>
  </required_header>
  <id_info>
    <org_study_id>soltsman2004.CTIL</org_study_id>
    <nct_id>NCT00461422</nct_id>
  </id_info>
  <brief_title>Early Follicular Supplementation of Ganirelix in IVF 2004</brief_title>
  <official_title>Early Follicular GnRH Antagonist Supplementation Improves Fertilization and Embryo Cleavage Rates in IVF-ET GnRH Antagonist Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Baruch Padeh Medical Center, Poriya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Organon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Baruch Padeh Medical Center, Poriya</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our goal was to investigate whether early follicular supplementation of the GnRH antagonist
      to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GnRH antagonist offers many advantages when used in IVF-ET treatment, however, it is
      suspected to yield lower pregnancy rate when compared with the long GnRH agonist protocol.

      Our goal was to investigate whether early follicular supplementation of the GnRH antagonist
      to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results.

      Consecutive patients are prospectively enrolled and randomly assigned to the study and
      control groups. Patients with low ovarian reserve or with uterine distortion are excluded
      from the study. Both groups are treated with recombinant FSH and the flexible GnRH antagonist
      protocol. Women in the study group are also treated with additional GnRH antagonist 0.25
      mg/day on day 1, 2 and 3 of the menstrual cycle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pregnancy rates</measure>
    <time_frame>one cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>differences in hormonal levels</measure>
    <time_frame>one cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>differences in the basic treatment doses</measure>
    <time_frame>one cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oocyte counts</measure>
    <time_frame>one cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fertilization rate</measure>
    <time_frame>one cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cleavage rate</measure>
    <time_frame>one cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Infertility</condition>
  <condition>IVF Treatment</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard Flexible antagonist protocol Addition of Ganirelix at first 3 days of the cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard Flexible antagonist protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganirelix</intervention_name>
    <description>sc injection of Ganirelix 0.25 mg per day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infertility

          -  IVF candidate

          -  failure of previous IVF attempt

        Exclusion Criteria:

          -  low ovarian reserve

          -  untreated distortion of uterine cavity

          -  medical contraindication for IVF treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yohnny S Younis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ministry of Health, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Baruch Padeh medical center, Poriya</name>
      <address>
        <city>Tiberias</city>
        <zip>15208</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2007</study_first_submitted>
  <study_first_submitted_qc>April 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2007</study_first_posted>
  <last_update_submitted>June 26, 2008</last_update_submitted>
  <last_update_submitted_qc>June 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2008</last_update_posted>
  <keyword>IVF</keyword>
  <keyword>GnRH antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

